These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31772533)

  • 1. Long-Term Outcomes of Extent of Revascularization in Complex High Risk and Indicated Patients Undergoing Impella-Protected Percutaneous Coronary Intervention: Report from the Roma-Verona Registry.
    Burzotta F; Russo G; Ribichini F; Piccoli A; D'Amario D; Paraggio L; Previ L; Pesarini G; Porto I; Leone AM; Niccoli G; Aurigemma C; Verdirosi D; Crea F; Trani C
    J Interv Cardiol; 2019; 2019():5243913. PubMed ID: 31772533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic utility of BCIS myocardial jeopardy score for classification of coronary disease burden and completeness of revascularization.
    De Silva K; Morton G; Sicard P; Chong E; Indermuehle A; Clapp B; Thomas M; Redwood S; Perera D
    Am J Cardiol; 2013 Jan; 111(2):172-7. PubMed ID: 23102883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamics and its predictors during Impella-protected PCI in high risk patients with reduced ejection fraction.
    Russo G; Burzotta F; D'Amario D; Ribichini F; Piccoli A; Paraggio L; Previ L; Pesarini G; Porto I; Leone AM; Niccoli G; Aurigemma C; Verdirosi D; Trani C; Crea F
    Int J Cardiol; 2019 Jan; 274():221-225. PubMed ID: 30057165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Impella protected-percutaneous coronary intervention on left ventricle function recovery of patients with extensive coronary disease and poor left ventricular function.
    Romagnoli E; Burzotta F; Cerracchio E; Russo G; Aurigemma C; Pedicino D; Locorotondo G; Graziani F; Leone AM; D'Amario D; Lombardo A; Malara S; Fulco L; Bianchini F; Sanna T; Trani C
    Int J Cardiol; 2023 Sep; 387():131098. PubMed ID: 37290663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six months follow-up of protected high-risk percutaneous coronary intervention with the microaxial Impella pump: results from the German Impella registry.
    Baumann S; Werner N; Al-Rashid F; Schäfer A; Bauer T; Sotoudeh R; Bojara W; Shamekhi J; Sinning JM; Becher T; Eder F; Akin I
    Coron Artery Dis; 2020 May; 31(3):237-242. PubMed ID: 31658135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unprotected versus protected high-risk percutaneous coronary intervention with the Impella 2.5 in patients with multivessel disease and severely reduced left ventricular function.
    Becher T; Eder F; Baumann S; Loßnitzer D; Pollmann B; Behnes M; Borggrefe M; Akin I
    Medicine (Baltimore); 2018 Oct; 97(43):e12665. PubMed ID: 30412063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of peri and post-procedural complications in patients undergoing revascularisation of coronary artery multivessel disease by coronary artery bypass grafting or protected percutaneous coronary intervention with the Impella 2.5 device.
    Becher T; Baumann S; Eder F; Perschka S; Loßnitzer D; Fastner C; Behnes M; Doesch C; Borggrefe M; Akin I
    Eur Heart J Acute Cardiovasc Care; 2019 Jun; 8(4):360-368. PubMed ID: 28660768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonemergent Percutaneous Coronary Intervention on an Unprotected Left Main Coronary Artery Supported with Impella® Heart Pump in Patients Ineligible for Surgical Revascularization.
    Meraj PM; Dixon S; Moses J; Ibrahim K; Schäfer A; Akin I; Hill J; Schreiber T; O'Neill WW
    J Interv Cardiol; 2019; 2019():9691753. PubMed ID: 31772553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of Impella-supported high-risk nonemergent percutaneous coronary intervention in a large single-center registry.
    Azzalini L; Johal GS; Baber U; Bander J; Moreno PR; Bazi L; Kapur V; Barman N; Kini AS; Sharma SK
    Catheter Cardiovasc Interv; 2021 Jan; 97(1):E26-E33. PubMed ID: 32333721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Clinical Correlates of Extended Mechanical Support in Patients Undergoing High-Risk Percutaneous Coronary Intervention in Current Clinical Practice: Insights from the cVAD Registry.
    Davila CD; Sharma S; Krishnamoorthy P; Rengifo-Moreno P; Palacios IF; O'Neill W; Kapur NK; Witzke CF
    Cardiovasc Revasc Med; 2020 Mar; 21(3):342-347. PubMed ID: 31227392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world supported unprotected left main percutaneous coronary intervention with impella device; data from the USpella registry.
    Schreiber T; Wah Htun W; Blank N; Telila T; Mercado N; Briasoulis A; Kaki A; Kondur A; Munir A; Grines C
    Catheter Cardiovasc Interv; 2017 Oct; 90(4):576-581. PubMed ID: 28417594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex High-Risk Indicated Percutaneous Coronary Intervention With Prophylactic Use of the Impella CP Ventricular Assist Device.
    van den Buijs DMF; van den Brink FS; Wilgenhof A; Zivelonghi C; Verouden N; Knaapen P; Sjauw KD; Vermeersch P; Nap A
    J Invasive Cardiol; 2022 Sep; 34(9):E665-E671. PubMed ID: 36001456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of left ventricular ejection fraction in high-risk percutaneous coronary interventions.
    Panoulas VF; Escaned J; Hill JM; Barker E; Butler K; Almedhychy A; Tsintzos SI; O'Neill WW
    Front Cardiovasc Med; 2024; 11():1342409. PubMed ID: 38370154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization.
    Head SJ; Milojevic M; Daemen J; Ahn JM; Boersma E; Christiansen EH; Domanski MJ; Farkouh ME; Flather M; Fuster V; Hlatky MA; Holm NR; Hueb WA; Kamalesh M; Kim YH; Mäkikallio T; Mohr FW; Papageorgiou G; Park SJ; Rodriguez AE; Sabik JF; Stables RH; Stone GW; Serruys PW; Kappetein AP
    J Am Coll Cardiol; 2018 Jul; 72(4):386-398. PubMed ID: 30025574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex-related difference in the use of percutaneous left ventricular assist device in patients undergoing complex high-risk percutaneous coronary intervention: Insight from the cVAD registry.
    Alraies MC; Kaki A; Kajy M; Blank N; Hasan R; Htun WW; Glazier JJ; Elder M; O'Neill WW; Grines CL; Schreiber T
    Catheter Cardiovasc Interv; 2020 Sep; 96(3):536-544. PubMed ID: 31631515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of Impella implantation and outcomes in cardiogenic shock or high-risk percutaneous coronary revascularization.
    Tarantini G; Masiero G; Burzotta F; Pazzanese V; Briguori C; Trani C; Piva T; De Marco F; Di Biasi M; Pagnotta P; Mojoli M; Casu G; Giustino G; Lorenzoni G; Montorfano M; Ancona MB; Pappalardo F; Chieffo A;
    Catheter Cardiovasc Interv; 2021 Aug; 98(2):E222-E234. PubMed ID: 33793051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Outcomes in Patients With Severely Reduced Left Ventricular Ejection Fraction Undergoing Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting.
    Sun LY; Gaudino M; Chen RJ; Bader Eddeen A; Ruel M
    JAMA Cardiol; 2020 Jun; 5(6):631-641. PubMed ID: 32267465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world use of the Impella 2.5 circulatory support system in complex high-risk percutaneous coronary intervention: the USpella Registry.
    Maini B; Naidu SS; Mulukutla S; Kleiman N; Schreiber T; Wohns D; Dixon S; Rihal C; Dave R; O'Neill W
    Catheter Cardiovasc Interv; 2012 Nov; 80(5):717-25. PubMed ID: 22105829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indication and short-term clinical outcomes of high-risk percutaneous coronary intervention with microaxial Impella® pump: results from the German Impella® registry.
    Baumann S; Werner N; Ibrahim K; Westenfeld R; Al-Rashid F; Sinning JM; Westermann D; Schäfer A; Karatolios K; Bauer T; Becher T; Akin I
    Clin Res Cardiol; 2018 Aug; 107(8):653-657. PubMed ID: 29520699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with end-stage renal disease requiring dialysis (5-year outcomes of the CREDO-Kyoto PCI/CABG Registry Cohort-2).
    Marui A; Kimura T; Nishiwaki N; Mitsudo K; Komiya T; Hanyu M; Shiomi H; Tanaka S; Sakata R;
    Am J Cardiol; 2014 Aug; 114(4):555-61. PubMed ID: 24996550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.